ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1PBLS | PARABILIS MEDICINES INC | Healthcare | $3.42B | 7.86% |
2ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 5.72% |
3HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 3.87% |
4PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 3.31% |
5LMRI | LUMEXA IMAGING HOLDINGS INC | Healthcare | $1.44B | 3.30% |
6KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 3.27% |
7INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 2.95% |
8PNTG | PENNANT GROUP INC | Healthcare | $1.26B | 2.90% |
9SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 2.56% |
10SPTX | SEAPORT THERAPEUTICS INC | Healthcare | $1.08B | 2.47% |
11ODTX | ODYSSEY THERAPEUTICS INC | Healthcare | $966M | 2.22% |
12BVS | BIOVENTUS INC | Healthcare | $915M | 2.10% |
13HSTM | HEALTHSTREAM INC | Healthcare | $867M | 1.99% |
14KIDS | ORTHOPEDIATRICS CORP | Healthcare | $851M | 1.95% |
15AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 1.70% |
16CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 1.66% |
17JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 1.62% |
18SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 1.40% |
19TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 1.38% |
20AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $571M | 1.31% |
21NRC | NRC HEALTH | Healthcare | $565M | 1.30% |
22SENS | SENSEONICS HOLDINGS INC | Healthcare | $550M | 1.26% |
23CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 1.23% |
24RGNX | REGENXBIO INC | Healthcare | $531M | 1.22% |
25TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 1.20% |
26SRTA | STRATA CRITICAL MEDICAL INC | Healthcare | $515M | 1.18% |
27RCEL | AVITA MEDICAL INC | Healthcare | $509M | 1.17% |
28ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 1.16% |
29DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 1.16% |
30OBIO | ORCHESTRA BIOMED HOLDINGS INC | Healthcare | $484M | 1.11% |
31EOLS | EVOLUS INC | Healthcare | $475M | 1.09% |
32CARL | CARLSMED INC | Healthcare | $474M | 1.09% |
33ARVN | ARVINAS INC | Healthcare | $450M | 1.03% |
34MOBI | MOBIA MEDICAL INC | Healthcare | $444M | 1.02% |
35SI | SHOULDER INNOVATIONS INC | Healthcare | $441M | 1.01% |
36PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.97% |
37PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.96% |
38NPCE | NEUROPACE INC | Healthcare | $413M | 0.95% |
39ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $411M | 0.94% |
40MASS | 908 DEVICES INC | Healthcare | $407M | 0.93% |
41LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.88% |
42FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.88% |
43EMBC | EMBECTA CORP | Healthcare | $364M | 0.84% |
44TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.80% |
45VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.79% |
46EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.75% |
47ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.75% |
48BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.73% |
49CV | CAPSOVISION INC | Healthcare | $314M | 0.72% |
50KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $311M | 0.71% |
51AGEN | AGENUS INC | Healthcare | $311M | 0.71% |
52TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.71% |
53INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.68% |
54OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.65% |
55FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.63% |
56SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.56% |
57LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.56% |
58UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.54% |
59DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.52% |
60GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.52% |
61PDEX | PRO DEX INC | Healthcare | $216M | 0.50% |
62AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.48% |
63ELMD | ELECTROMED INC | Healthcare | $204M | 0.47% |
64TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.46% |
65KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.45% |
66KRRO | KORRO BIO INC | Healthcare | $196M | 0.45% |
67RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.45% |
68ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.43% |
69ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.42% |
70OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.38% |
71STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.37% |
72INGN | INOGEN INC | Healthcare | $146M | 0.34% |
73SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.28% |
74BDSX | BIODESIX INC | Healthcare | $109M | 0.25% |
75IMUX | IMMUNIC INC | Healthcare | $106M | 0.24% |
76PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.23% |
77CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.23% |
78ICCC | IMMUCELL CORP | Healthcare | $93M | 0.21% |
79JYNT | JOINT CORP | Healthcare | $92M | 0.21% |
80RLYB | RALLYBIO CORP | Healthcare | $84M | 0.19% |
81VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.19% |
82NRXS | NEURAXIS INC | Healthcare | $82M | 0.19% |
83ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.19% |
84NTRB | NUTRIBAND INC | Healthcare | $73M | 0.17% |
85GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.16% |
86XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.13% |
87POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.13% |
88COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.12% |
89YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.12% |
90ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.12% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $43.54B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 19% toward Large, 27% toward Growth. +8% unclassified (11 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 90 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Days required to liquidate the largest position at 20% of one day's dollar volume.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 90 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 24.3% | 2.9% |
| 3 yearsp.a. | 19.7% | 3.5% |
| 5 yearsp.a. | -2.9% | -11.6% |
| 10 yearsp.a. | 3.2% | -8.4% |
| Since inceptionp.a. | 7.6% | -1.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 22.2% | -0.5% |
| 2025 | 23.5% | 5.5% |
| 2024 | -2.2% | -5.5% |
| 2023 | -11.2% | -13.6% |
| 2022 | -33.6% | -31.3% |
| 2021 | -5.2% | -24.0% |
| 2020 | 22.9% | 6.3% |
| 2019 | 32.7% | 10.8% |
| 2018 | -4.2% | -10.3% |
| 2017 | 6.3% | -12.1% |
| 2016 | -9.8% | -3.4% |
| 2015 | 2.9% | -3.2% |
| 2014 | 15.5% | -8.1% |
| 2013 | 70.8% | 20.7% |
| 2012 | 26.2% | 7.7% |
| 2011 | -10.5% | -20.0% |
| 2010 | 17.0% | 13.2% |
| 2009 | 3.2% | -14.9% |
| 2008 | -39.6% | -21.5% |
| 2007 | -7.8% | -13.6% |
| 2006 | 15.5% | 9.2% |
| 2005 | 12.8% | 3.0% |
| 2004 | 23.8% | 21.5% |
| 2003 | 155.4% | 119.1% |
| 2002 | -60.9% | -48.1% |
| 2001 | -8.4% | 3.9% |
| 2000 | 46.6% | -1.5% |
| 1999 | 87.2% | 90.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare VolSD Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a VolSD signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.